NEWS
Our Latest News
ARCHIMED acquires SeqCenter, a fast-growing player in cutting-edge DNA and RNA gene sequencing
SeqCenter is a category leader in Next-Generation Sequencing, which can sequence hundreds of thousands of genes in record-time and at low cost.
Global private equity healthcare specialist ARCHIMED announces the acquisition of Pittsburgh, Pennsylvania-based genetic sequencing provider SeqCenter. SeqCenter’s founding scientists initially worked at the University of Pittsburgh. Frustrated with the pace, cost and difficulty of obtaining sequencing data from existing vendors and academic core laboratories, they developed their own approach to gene sequencing, ultimately leaving academia and founding SeqCenter in 2019.
ARCHIMED concludes successfully its £203 million take-private bid for drug development software leader Instem
November
27,
2023
ARCHIMED creates a leading specialized dermatological-focused CRO via the simultaneous purchase & merger of Symbio and Proinnovera
November
17,
2023
ARCHIMED top-ranked buyout fund MED I earns 4.5x on the sale of Vita
October
27,
2023
368